Humanigen (Humanigen) 12-1 Month Momentum % : -99.81% (As of Apr. 28, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Humanigen 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-28), Humanigen's 12-1 Month Momentum % is -99.81%.

The industry rank for Humanigen's 12-1 Month Momentum % or its related term are showing as below:

HGENQ's 12-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -20.83 vs HGENQ: -99.81

Competitive Comparison of Humanigen's 12-1 Month Momentum %

For the Biotechnology subindustry, Humanigen's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humanigen's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Humanigen's 12-1 Month Momentum % falls into.

Humanigen (OTCPK:HGENQ) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humanigen (OTCPK:HGENQ) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Humanigen 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Humanigen's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Humanigen (Humanigen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078

Website

https://www.humanigen.com

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Executives

Dale Chappell	10 percent owner	C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne	officer: Chief Medical Officer	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant	director	90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan	officer: Chief Commercial Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie	director	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp	10 percent owner	C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd.	10 percent owner	C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd.	10 percent owner	C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton	director	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd.	10 percent owner	P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc	10 percent owner	C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester	officer: Chief Financial Officer	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022